Fig. 6: Extrachromosomal DNA amplification is prognostic of overall survival in anti-PD1 monotherapy. | Nature Communications

Fig. 6: Extrachromosomal DNA amplification is prognostic of overall survival in anti-PD1 monotherapy.

From: Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer

Fig. 6

Kaplan-Meier overall survival (OS) curve comparisons between patients with ecDNA amplification and patients without ecDNA amplification in a the SYSUCC advanced gastric cancer cohort and (b) the SYSUCC nasopharyngeal carcinoma cohort. Patients in both two cancer cohorts are treated with anti-PD-1 drug toripalimab. Log-rank test P value and hazard ratio are shown. c–d Forest plots of multivariable overall survival Cox regression analysis for focal amplification subtypes with known immunotherapy biomarkers and other variables as control factors in (a) the SYSUCC nasopharyngeal carcinoma cohort and b the SYSUCC nasopharyngeal carcinoma cohort. The point estimations of hazard ratio derived from Cox regression test and their corresponding 95% confidence level intervals (error bars) are presented. TMB_status tumor mutation burden status. Here median as a cutoff is adopted for classifying TMB and aneuploidy into high and low groups. Source data are provided as a Source Data file.

Back to article page